SIRT3 and metabolic dysfunction-associated steatotic liver disease: This AMPK-dependent signaling, together with more direct modulation of sirtuins (SIRT1 and SIRT3), drives PGC-1α activation, mitochondrial biogenesis, and reprogramming of substrate use, including enhanced fatty acid oxidation and reduced hepatic gluconeogenesis in models of obesity, diabetes, and non-alcoholic fatty liver disease [20,21].